Pila Pharma AB
F:5KC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pila Pharma AB
F:5KC
|
SE |
|
S
|
Sumitomo Electric Industries Ltd
OTC:SMTOY
|
JP |
|
BIO-Key International Inc
OTC:BKYI
|
US |
|
R
|
Ryohin Keikaku Co Ltd
SWB:3RK
|
JP |
|
Vistra Corp
LSE:0A8O
|
US |
|
R
|
Renault SA
XHAM:RNL
|
FR |
Pila Pharma AB
Pila Pharma AB engages in conducting research and experimental pharmaceutical development. The company is headquartered in Malmo, Skane. The company went IPO on 2021-07-15. The firm conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
Pila Pharma AB engages in conducting research and experimental pharmaceutical development. The company is headquartered in Malmo, Skane. The company went IPO on 2021-07-15. The firm conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
